Building a  long-term pipeline Cumberland is committed to identifying and  nurturing early stage product candidates through  its majority-owned subsidiary, Cumberland  Emerging Technologies (CET). Established  in partnership with Vanderbilt University and  Launch Tennessee, CET bridges the development  gap between the research laboratory and the  commercial marketplace by providing researchers,  universities and entrepreneurs with a commercial  development infrastructure for promising biomedical  technologies.  In May, Cumberland and China’s Gloria  Pharmaceuticals made a combined $2 million  investment in CET as part of a joint research and  development initiative. The funds will be used to  accelerate development of CET’s pipeline of new  product candidates emerging from Vanderbilt  University and other regional research centers.  Gloria Pharmaceuticals, which also serves as  Cumberland’s commercial partner for Acetadote ® and Caldolor ®  in China, will have the first opportunity  to negotiate a license to CET products for China  while Cumberland will retain access to CET’s  products for the rest of the world. CET partners with leading academic research  centers throughout the mid-south region of the  United States to evaluate emerging technologies  with high commercial potential. By teaming  with scientists to develop promising candidates,  Cumberland is building a long-term pipeline while  accelerating biomedical innovation. This strategy  paved the way for the Company’s acquisition of  ifetroban, which is currently being developed under  the brand name Hepatoren, from CET in 2011. CET Life  Sciences  Center 12 In addition to its partnerships with leading academic research centers,  CET fosters innovation through the CET Life Sciences Center, a business  incubator facility that provides laboratory and office space, equipment  and infrastructure to early-stage biomedical companies. Located in the  heart of downtown Nashville and just minutes away from the Vanderbilt  University medical research facilities, the recently expanded facility offers  a collaborative setting to support other life sciences initiatives. 